InsiderSignal.AI

InsiderSignal.ai

VERA - Vera Therapeutics, Inc.

Insider Sale by Fordyce Marshall (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Fordyce Marshall, serving as Pres, CEO at Vera Therapeutics, Inc. (VERA), sold 22,951 shares at $44.05 per share, for a total transaction value of $1,011,051.00. Following this transaction, Fordyce Marshall now holds 457,274 shares of VERA.

This sale represents a 5.00% decrease in Fordyce Marshall's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, April 14, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 15, 2026, 1 day after the trade was made.

Vera Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Fordyce Marshall

Fordyce Marshall

Pres, CEO

Marshall Fordyce, MD is the founder and CEO of Vera Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for autoimmune and rare immunologic diseases[[1]](https://www.biotech2050.com/episodes/verafeb22-tsgc5)[[2]](https://xtalks.com/combating-autoimmunity-vera-therapeutics-ceo-dr-marshall-fordyce-discusses-advancing-igan-treatments-episode-202/). With over 15 years of experience leading teams in drug discovery, development, clinical translation, and commercialization, Fordyce brings extensive expertise to his leadership role[[1]](https://www.biotech2050.com/episodes/verafeb22-tsgc5). He founded Vera in 2016 as an entrepreneur in residence at Kleiner Perkins Caufield and Byers, and successfully took the company public in 2021[[2]](https://xtalks.com/combating-autoimmunity-vera-therapeutics-ceo-dr-marshall-fordyce-discusses-advancing-igan-treatments-episode-202/). Under his direction, Vera has raised over $1 billion in capital and advanced its lead molecule, atacicept, through a successful Phase II trial in IgA nephropathy, with Phase III results met in June 2025[[2]](https://xtalks.com/combating-autoimmunity-vera-therapeutics-ceo-dr-marshall-fordyce-discusses-advancing-igan-treatments-episode-202/)[[6]](https://veratx.com/about/). Prior to founding Vera, Fordyce served as Senior Director of Clinical Research at Gilead Sciences, where he contributed to seven new drug approvals and led the company's TAF/GENVOYA development program, driving innovation in HIV and hepatitis treatments[[1]](https://www.biotech2050.com/episodes/verafeb22-tsgc5)[[2]](https://xtalks.com/combating-autoimmunity-vera-therapeutics-ceo-dr-marshall-fordyce-discusses-advancing-igan-treatments-episode-202/). He previously founded and served as CEO of gene-editing company Trucode Gene Repair, Inc.[[1]](https://www.biotech2050.com/episodes/verafeb22-tsgc5). Fordyce holds a BA from Harvard University and an MD from Harvard Medical School, with subspecialty training in infectious disease from Columbia University Vagelos College of Physicians and Surgeons[[1]](https://www.biotech2050.com/episodes/verafeb22-tsgc5). He served as Chief Resident at NYU Bellevue and completed two years as a translational research fellow at Rockefeller University[[1]](https://www.biotech2050.com/episodes/verafeb22-tsgc5). Fordyce currently serves on the Board of Directors and as Treasurer of the Albert and Mary Lasker Foundation[[2]](https://xtalks.com/combating-autoimmunity-vera-therapeutics-ceo-dr-marshall-fordyce-discusses-advancing-igan-treatments-episode-202/).

View full insider profile →

Trade Price

$44.05

Quantity

22,951

Total Value

$1,011,051.00

Shares Owned

457,274

Trade Date

Tuesday, April 14, 2026

2 days ago

SEC Filing Date

Wednesday, April 15, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Vera Therapeutics, Inc.

Company Overview

No company information available
View news mentioning VERA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5667073

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime